Markets:

Overview

News

Currencies

International

Treasuries

Anixa Biosciences, Inc. - Common Stock (NQ:ANIX)

2.810 +0.040 (+1.44%)

Delayed Quote Updated: 9:41 AM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Anixa Biosciences, Inc. - Common Stock

< Previous 1 2 Next >

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 17, 2026

Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market session. The market value of their outstanding shares is at $112.9 million. Barinthus Biotherapeutics...

Via Benzinga

3 Under-the-Radar Biotechs Under $5 That Could Soar 200% ↗

September 09, 2025

3 biotech stocks under $5 with cancer, obesity, and psychedelic therapies offer speculative investors high-risk, high-reward potential: HOTH, SILO, and ANIX.

Via MarketBeat

EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent ↗

April 09, 2025

Anixa secures USPTO patent for its breast cancer vaccine using α-lactalbumin, enhancing its IP portfolio and expanding future immunotherapy options.

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 08, 2025

Via Benzinga

Recap: Anixa Biosciences Q1 Earnings ↗

March 12, 2024

Via Benzinga

6 Analysts Have This to Say About Anixa Biosciences ↗

June 19, 2023

Via Benzinga

The Latest Analyst Ratings for Anixa Biosciences ↗

May 23, 2023

Via Benzinga

Expert Ratings for Anixa Biosciences ↗

April 18, 2023

Via Benzinga

EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines ↗

March 25, 2025

Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer vaccines, with U.S. trials planned.

Via Benzinga

EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine ↗

March 24, 2025

Anixa Biosciences secured a USPTO patent allowance for its ovarian cancer vaccine, strengthening its IP position and advancing its clinical development.

Via Benzinga

Topics Intellectual Property

This ACNB Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday ↗

March 21, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 30, 2024

Via Benzinga

Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying ↗

July 29, 2024

Via Benzinga

EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy ↗

July 23, 2024

FDA Approves Anixa Biosciences' Ovarian Cancer CAR-T Therapy for Individual Patient Trial. Moffit Cancer Center receives approval for a second dose in an ongoing Phase I trial showing early promising...

Via Benzinga

EXCLUSIVE: Anixa Biosciences Finds Stock Undervalued, Launches $5M Stock Buyback Program ↗

July 15, 2024

Anixa Biosciences announces $5 million share repurchase program due to undervalued stock. Partnership with Cleveland Clinic for cancer vaccines.

Via Benzinga

ANIX Stock Earnings: Anixa Biosciences Beats EPS for Q2 2024 ↗

June 04, 2024

ANIX stock results show that Anixa Biosciences beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

7 Penny Biotech Stocks to Triple Your Investment ↗

May 28, 2024

Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns.

Via InvestorPlace

Anixa Biosciences, A New Type Of Biotech Company: Could It Disrupt The Cancer Landscape? ↗

December 20, 2023

Anixa Biosciences (NASDAQ: ANIX) is an interesting, undiscovered biotech company that seeks to disrupt the cancer landscape by working with some highly credible partners. The company is undiscovered...

Via Benzinga

3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023 ↗

December 11, 2023

Some of the most explosive opportunities can be found in biotech stocks. In fact, as we head into New Year 2024, here are three to consider.

Via InvestorPlace

Anixa Biosciences Reveals Updated Data From Breast Cancer Vaccine Trial, Says 'Exceeded Expectations' ↗

December 07, 2023

Anixa Biosciences Inc (NASDAQ: ANIX) announced new and updated results from the Phase 1 trial of its breast cancer vaccine.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 07, 2023

Via Benzinga

The 3 Most Undervalued Cheap Stocks to Buy in September 2023 ↗

September 11, 2023

These cheap stocks to buy are the ones for long term growth and high returns in your investment portfolio.

Via InvestorPlace

Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer? ↗

August 09, 2023

Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventing the disease. However, recent research on the...

Via Benzinga

Anixa Biosciences And 2 Other Penny Stocks Insiders Are Aggressively Buying ↗

July 24, 2023

The Dow Jones edged higher on Friday, recording gains for the tenth straight session. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects....

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 23, 2023

Via Benzinga

Appreciating The Passing Of A Titan & Incorporating Alternative Data Signals ↗

December 27, 2022

Kathleen Moriarty, the lawyer who helped develop the structure for SPY and a true co-founder of the ETF industry, passed away last week.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For December 23, 2022 ↗

December 23, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

December 09, 2022

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 10, 2022

Gainers Reshape Lifesciences (NASDAQ:RSLS) shares increased by 12.7% to $0.34 during Monday's after-market session. The market value of their outstanding shares is at $1.2 million.

Via Benzinga

Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday ↗

September 19, 2022

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.